|Bid||14.92 x 1000|
|Ask||15.19 x 2200|
|Day's Range||14.83 - 15.42|
|52 Week Range||11.55 - 26.99|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Actions speak louder than words, as the saying goes. And when it comes to insiders, that certainly seems to be the case. If we track informative insider buy transactions, we can get an idea of the stocks that insiders see as compelling investing opportunities right now. As insiders have access to a wealth of company information, these insights can be very valuable when deciding which stocks to buy or sell. With that in mind we took a closer look at three stocks insiders are snapping up right now: Immunomedics (IMMU)Immunomedics focuses on the development of antibody-drugs for the treatment of cancer. Most notably sacituzumab has received Breakthrough Therapy designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who failed previous therapies. It’s also granted the drug fast track designation for lung cancer treatment. Shares have surged 12% in the last five days, and that’s partly down to an influx of insider money. Most notably, corporate director and owner venBio Select Advisor LLC recently picked up a whopping $13.5 million worth of stock. That brings venBio’s total holding of IMMU to just over $298 million. And it’s not just insiders that are bullish. The stock also shows a ‘Strong Buy’ analyst consensus with an average price target of $23- indicating that further upside potential of 54% lies ahead. “As we expect sacituzumab to address a major unmet need in the treatment of r/r mTNBC [metastatic triple negative breast cancer] next year, we continue to think that IMMU is undervalued for its potential” comments Cowen & Co analyst Phil Nadeau. “We continue to expect sacituzumab will become a standard mTNBC treatment upon its approval” the analyst added. He notes that Daiichi’s DS-1062a has the potential to be long-term competition to IMMU's sacituzumab- but reassures investors that IMMU is clearly well ahead. “Given sacituzumab's several-year lead, it will be incumbent upon DS-1062a to show meaningful advantages in order to displace it” the analyst writes. Fastly Inc (FSLY)Cloud computing services provider Fastly is a newcomer to the markets. The company, which helps companies deliver online content more quickly, debuted on the NYSE back in May. Its IPO was a great success; the company sold 11.25 million shares at $16 each, bringing returns of $180 million. Since the IPO shares have surged to the current price of $20.55.And now we can see that insiders are already pouring more money into this fast-growing tech stock. Abdiel Capital Management, one of the company’s owners, has just picked up a further $7.62 million of FSLY stock. This brings the total holding to $78.8 million. No doubt this move would make sense to five-star analyst Brad Reback of Stifel Nicolaus. He initiated coverage of the stock with a buy rating and $25 price target (22% upside potential). The analyst contends: “In the coming years, we believe Fastly can leverage its superior technological approach to drive continued strong net new customer additions and expand its wallet share among its existing installed base.” Combined with a large market opportunity and the ability to further penetrate international markets, Reback is confident that Fastly can sustain at least a 30% top-line growth profile. Myovant Sciences (MYOV)Myovant Sciences is a clinical-stage biopharma developing therapies for women’s health and endocrine diseases. Shares have crashed 47% year-to-date, with the selloff prompted by the release of relugolix phase 3 uterine fibroids data. Investors are concerned about Abbvie’s (ABBV) uterine fibroid rival, Orlissa.However, insiders are demonstrating their confidence in the company. In the last three months insiders have bought a whopping $160 million of shares. That includes a $45,000 purchase from director Sebelius Kathleen, as well as $20 million from owner Viking Global Investors. Indeed, all ten transactions in the last month are positive insider buy transactions- with only one insider sell transaction recorded four months ago.Furthermore, the Street is also staying onside. All five analysts covering the stock rate Myovant a ‘buy.’ That gives the stock its ‘Strong Buy’ analyst consensus. Meanwhile their average price target of $26 indicates massive upside potential of 194%. Analysts argue that the stock looks oversold at current levels, with Barclays analyst Geoffrey Meacham saying he still believes Myovant’s relugolix has a favorable profile compared to rival offerings. Meanwhile five-star Evercore ISI analyst Ravi Mehrotra is anticipating revenues of $944M for relugolix by 2023 due to its "commercial advantage of a one-a-day pill." Discover more Hot Insider Trading Stocks here
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Health care companies featured prominently in the week's insider purchases. MGM Resorts International (NYSE: MGM) had a director continue to make indirect share purchases this past week. MGM stock rose about 2% in the past week, while the S&P 500 was essentially flat.
Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. MGM Resorts International (NYSE: MGM) saw a director making indirect share purchases this past week.
The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.
The Morris Plains, New Jersey-based company said it had a loss of 46 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
Today we will run through one way of estimating the intrinsic value of Immunomedics, Inc. (NASDAQ:IMMU) by taking the expected future cash flows and discounting them to their present value. I will be using the Discounted Cash...
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 25.69% for Immunomedics (IMMU) based on the company’s closing price on
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Stocks with market capitalization between $2B andRead More...
Immunomedics (IMMU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
[Editor's note: This story was originally published February 2018.] Even after all the tough breaks the market had in December, the recent turnaround suggests maybe things weren't as dire as they looked. Still there are some companies that could disappear before this year is out. The sad reality is, some companies are too far gone to salvage no matter how well the economy performs in 2019. Profit margins aren't necessarily the problem with a lot of these companies. The problem could be the product or service itself or a horrible reputation that would-be customers just can't shrug off. InvestorPlace - Stock Market News, Stock Advice & Trading Tips With that as the backdrop, here are the eight major companies most likely to pull a vanishing act in 2019. These are companies that could disappear either completely or just in their current form. Their brand names may survive, but the operations themselves simply aren't viable enough. * 7 Stocks That Won Super Bowl Sunday Source: GoPro ### GoPro (GPRO) Just to be clear, you'll likely find GoPro-branded action cameras on store shelves for many years to come. In the same sense Xerox and Google transcended company names and became verbs, GoPro (NASDAQ:GPRO) has successfully become synonymous with action cameras. GoPro is and will remain the standard-bearer for its respective market. That market, however, has been surprisingly small, with no real barrier to entry. The end result? Last year's earnings were abysmal and revenue was flat for the full year. The company is still booking heavy losses too, unable to find or develop a product more consumers just have to have. Even though CEO Nick Woodman held out hope for a buyout of GoPro last year, nobody bit. And at this point it doesn't looks as if anyone will soon. GoPro owners hoping for a generous buyout offer may not want to hold their breath. Source: Shutterstock ### Container Store Group (TCS) The Container Store (NYSE:TCS) still operates more than 80 stores in the U.S. albeit it with much less visibility than it enjoyed several years ago (the last time organization was all the rage). Between cheaper options online and the move from venues like Bed Bath & Beyond (NASDAQ:BBBY) and home improvement retailers like Home Depot (NYSE:HD) to get deeper into the organizational market, The Container Stores simply became less of a draw. * 10 F-Rated Stocks That Could Break Your Portfolio Even though The Container Store got a 50% bounce in January allegedly thanks to the Marie Kondo show, the marketplace isn't going to change back to what it once was. CEO Melissa Reiff should recognize it's better to cash out when there's still something of value left cash out. ### Neiman Marcus Neiman Marcus is not a publicly-traded company, but a noteworthy name to investors all the same. The struggles that the department store chain faces are applicable to other similar chains. Last year CreditRiskMonitor warned that Neiman Marcus' risk of declaring bankruptcy in 2019 was as high as 50%. Over the last two weeks the company seems to be attempting to mount a turnaround with the departure of president and marketing director James Gold and hiring talent away from Apple (NASDAQ: AAPL) and Starboard Cruise Services. But whether these moves can save this company is debatable. The math just doesn't work unless the company can sell more merchandise to more customers at higher prices. Something's got to give sooner or later, and sooner rather than later. Source: Shutterstock ### Immunomedics (IMMU) Investors who've been following the Immunomedics (NASDAQ:IMMU) story for the past several years will know that 2017 was a pivotal year for the company. Sales last year of its oncology diagnostics product LeukoScan were brisk but the FDA denied its request to accelerate approval of Sacituzumab Govitecan. Moreover, aside from the sale of its revenue-bearing LeukoScan intellectual property, it already has sold royalty rights for Sacituzumab Govitecan to Royalty Pharma. * 7 S&P 500 Stocks to Buy That Tore Up Earnings If you read between the lines and study the long-term case, you see that Immunomedics realizes it's running out of money at a pretty quick clip. In fact, the company intends to sell its LeukoScan franchise to help fund the development of the more promising opportunities in that pipeline. There's just not enough money coming in to carry all the weight the company needs carried. Source: Shutterstock ### Remington Remington is another privately-held company that investors may want to keep close tabs on, as what's happening to it could apply to rivals like Sturm Ruger & Company Inc (NYSE:RGR). The firearm manufacturer just barely was able to emerge from bankruptcy. This may be a case, however, where restructuring and more time don't solve the true, underlying problem. That is that consumers just don't want the guns Remington is making. Remington was sued over the 2012 Sandy Hook shooting, and many investors have distanced themselves since. This, along with potential for stricter gun laws in the foreseeable future, means there may not be any growth in Remington's futures. Source: Shutterstock ### Sears (SHLD) The company's downfall has been predicted many times before. With each passing year, however, Sears (NASDAQ:SHLD) moves closer to the edge of the cliff. This year may be the year it finally falls off. It recently escaped liquidation by the skin of its teeth when hedge-fund manager Edward Lampert put up $5.3 billion to keep Sears solvent, for now. But the thing is, Sears hasn't turned a full-year profit since 2011. Lampert spent last year breaking Sears into pieces and he's running out of things to sell as the company continues bleeding income. Source: Shutterstock ### Southeastern Grocers You've probably not heard of Southeastern Grocers. That's because, aside from not being a publicly-traded entity, it doesn't do business under its corporate name. You've probably heard of its stores though, particularly if you're from the south. It's the owner of BI-LO, Harveys, Winn-Dixie and Fresco y Mas grocery stores, some of which have been around for eons. Right now, Southeastern Grocers is the nation's eleventh-largest grocery store network. In the modern era, however, that isn't a whole lot better than being the fiftieth largest. It's business that relies on scale, and lots of it. Kroger Co (NYSE:KR) and Amazon.com, Inc. (NASDAQ:AMZN) have it. Southeastern Grocers doesn't. Last year, chatter first surfaced that the company wouldn't even come close to making the full service payments due on its $1 billion in debt. Increasingly, it looks as if it will fall to Amazon before too long. Source: Fitbit ### Fitbit (FIT) Last but not least, add Fitbit Inc (NYSE:FIT) to your list of companies that won't be around as you know and love them today. Like GoPro and Sears, you can reasonably expect consumer technology with the Fitbit name on them to still be in stores come 2020. The organization has worked hard to develop the brand into the name people think of when they think of wearables. Much like GoPro though, this is a company that thought its wares were far more marketable then they actually were. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Boring Stocks to Buy for Red-Hot Returns * The 7 Best Car Stocks to Park in Your Portfolio * 7 Beaten-Down Chinese Stocks Ready to Rebound Compare Brokers The post 8 Companies That Could Disappear Before 2019 Is Over appeared first on InvestorPlace.
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics stock is taking a beating on Friday after receiving a response from the U.S. Food and Drug Administration (FDA) concerning one of its drugs. Source: Shutterstock Immunomedics (NASDAQ:IMMU) notes that it has received a Complete Response Letter from the FDA in response to its request for "accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer." The bad news here for Immunomedics stock is what a Complete Response Letter from the FDA means. This is what the government agency sends out to companies when it has decided that the application is not ready for approval. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Retail Stocks to Buy for the Rise of Menswear Here is the response from Immunomedics President and CEO Michael Pehl to the Complete Response Letter from the FDA. "We believe in sacituzumab govitecan's potential to be a viable treatment option for these patients. The issues related to approvability in the CRL were exclusively focused on Chemistry, Manufacturing and Control matters and no new clinical or preclinical data need to be generated. We are going to request a meeting with the FDA as soon as possible to gain a full understanding of the Agency's requirements and timelines for approval and we will work closely with the FDA with the goal of bringing this important medicine to patients as soon as possible." Despite the positive outlook on the matter from the company's President and CEO, investors still weren't happy with the news. This caused IMMU stock to fall by 26% as of Friday afternoon. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Apple Should Consider Buying * 7 Beaten-Up Housing Stocks Due for a Bounce Back * Take Buffett's Advice: 5 Vanguard Funds to Buy As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post Why Immunomedics Stock Is Getting Hammered Today appeared first on InvestorPlace.